Funding for this research was provided by:
Received: 21 June 2018
Accepted: 31 May 2019
First Online: 4 July 2019
Ethics approval and consent to participate
: Data collection was conducted per the European Pharmaceutical Market Research Association (EphMRA) code of conduct and did not require Clinical Research Ethics Committee or Independent Review Board approval (Institutional Review Board in the US). Data were subsequently anonymized, in compliance with the Health Insurance Portability and Accountability Act (HIPAA) and Health Information Technology for Economic and Clinical Health (HITECH) regulations in the US.
: All results presented in this manuscript are in aggregate form and no personal identifiable information was used for this study.
: WW is an employee of Regeneron Pharmaceuticals, Inc., and a former employee of Sanofi and may hold stock and/or stock options in both companies. ES, SB, and JP are employees of Adelphi Real World, under contract with Sanofi. C-IC is an employee of Regeneron Pharmaceuticals, Inc. and may hold stock and/or stock options in the company. JRC received consulting fees, speaking fees, or honoraria from AbbVie, Bristol-Myers Squibb, Eli Lilly, Myriad, Roche/Genentech, and UCB and for < $10,000; and from Amgen, Corrona, Janssen, and Pfizer for >$10,000.